A prospective clinical trial of green tea for hormone refractory prostate cancer: an evaluation of the complementary/alternative therapy approach.

@article{Choan2005APC,
  title={A prospective clinical trial of green tea for hormone refractory prostate cancer: an evaluation of the complementary/alternative therapy approach.},
  author={E Choan and Roanne J. Segal and Derek I. Jonker and Shawn Christopher Malone and Neil Reaume and Libni J. Eapen and Victor Gallant},
  journal={Urologic oncology},
  year={2005},
  volume={23 2},
  pages={108-13}
}
PURPOSE To evaluate the efficacy and toxicity of green tea, prescribed as an alternative complementary (CAM) formulation on hormone refractory prostate cancer (HRPC). METHODS Patients with HRCP were prescribed green tea extract capsules at a dose level of 250 mg twice daily. Efficacy and toxicity were evaluated during monthly visits. The primary endpoint was prostate-specific antigen (PSA) or measurable disease progression after a minimum of 2 months of therapy. RESULTS Nineteen patients… CONTINUE READING